11 investors predict a colorful, if difficult, future for psychedelic startups
TechCrunch
MAY 12, 2023
Amongst these questions are actual costs of therapies, reimbursement coverage, the commercialisation strategy for psychedelic drug development companies, resource bottlenecks with the therapists’ supply and infrastructure, etc,” they told TechCrunch+. is discussed,” said Amy Kruse, chief investment officer, Satori Neuro.
99 
Let's personalize your content